Bio Green Med Solution (BGMS)
NASDAQ:BGMS
Want to see BGMS full AI Analyst Report?
BGMS Stock Chart & Stats
$1.45
--
Market closed
$1.45
--
Day’s Range― - ―
52-Week Range$0.73 - $27.27
Previous CloseN/A
VolumeN/A
Average Volume (3M)473.94K
Market Cap
$5.80M
Enterprise Value-$936.37K
Total Cash (Recent Filing)$3.34M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield10.27%
Share Statistics
EPS (TTM)-4.40
Shares Outstanding5,519,456
10 Day Avg. Volume1,252,948
30 Day Avg. Volume473,939
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.47
Price to Sales (P/S)4.33
P/FCF Ratio-0.68
Enterprise Value/Market Cap-0.16
Enterprise Value/Revenue-0.61
Enterprise Value/Gross Profit-3.36
Enterprise Value/Ebitda0.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-268.8
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Rapid Revenue GrowthSustained TTM revenue growth above 100% demonstrates accelerating commercial traction from the company’s new product mix. This scale expansion provides a structural base to improve unit economics and absorb fixed costs, supporting longer-term margin recovery if growth persists.
Low Leverage / Improved CapitalizationA debt-free balance sheet materially lowers solvency risk and preserves financial flexibility across 2-6 months. Improved equity vs prior negative levels strengthens capitalization, enabling management to prioritize operational turnaround or opportunistic M&A without immediate debt service constraints.
Strategic Pivot To Fire SafetyThe structural shift from biopharma to fire-safety distribution and the Fitters acquisition create a clearer, revenue-generating business model. Lower R&D and focused operations reduce cash burn risk and improve predictability of product sales across relevant regional markets over the medium term.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flows indicate the business still consumes cash despite improvements. Ongoing burn creates structural funding risk, likely necessitating external financing or equity raises that could dilute existing shareholders and constrain strategic investments.
Deep Operating Losses And Weak MarginsVery low gross margin and extreme negative operating/net margins show the cost base far exceeds current revenue scale. Without durable margin expansion or significant cost restructuring, the company faces structural difficulty achieving profitability and generating sustainable returns.
Preferred Share Delisting / Liquidity ImpactDelisting of convertible preferred shares is a lasting change to capital-market access and liquidity for that security. It can impede future preferred financing, complicate the capital structure, and reduce investor access to the company’s funding alternatives over the medium term.
Bio Green Med Solution News
BGMS FAQ
What was Bio Green Med Solution’s price range in the past 12 months?
Bio Green Med Solution lowest stock price was $0.73 and its highest was $27.27 in the past 12 months.
What is Bio Green Med Solution’s market cap?
Bio Green Med Solution’s market cap is $5.80M.
When is Bio Green Med Solution’s upcoming earnings report date?
Bio Green Med Solution’s upcoming earnings report date is Aug 12, 2026 which is in 73 days.
How were Bio Green Med Solution’s earnings last quarter?
Bio Green Med Solution released its earnings results on May 14, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.04.
Is Bio Green Med Solution overvalued?
According to Wall Street analysts Bio Green Med Solution’s price is currently Overvalued.
Does Bio Green Med Solution pay dividends?
Bio Green Med Solution pays a Notavailable dividend of $0.15 which represents an annual dividend yield of 10.27%. See more information on Bio Green Med Solution dividends here
What is Bio Green Med Solution’s EPS estimate?
Bio Green Med Solution’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bio Green Med Solution have?
Bio Green Med Solution has 5,519,456 shares outstanding.
What happened to Bio Green Med Solution’s price movement after its last earnings report?
Bio Green Med Solution reported an EPS of -$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.143%.
Which hedge fund is a major shareholder of Bio Green Med Solution?
Currently, no hedge funds are holding shares in BGMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bio Green Med Solution
A diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in biopharmaceutical research and fire safety solutions to create sustainable long-term shareholder value.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Rein Therapeutics
―
Bluejay Diagnostics
―
Neuphoria Therapeutics
―
Ownership Overview
57.05% Insiders
0.03% Mutual Funds
<0.01% Other Institutional Investors
42.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---